Clinical trials: Radioligand
Metastatic Castration-resistant Prostate Cancer
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the…
- Trial name
- NCT04225910
- Testing
- 225Ac-PSMA
- Volunteers
- 20 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Refractory Solid Tumor
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
Increased fibroblast activation protein expression is positively correlated with the aggressiveness of cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel…
- Trial name
- NCT05963386
- Testing
- 177Lu-DOTA-EB-FAPI radionuclide therapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Prostate Cancer
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic…
- Trial name
- AcTFirst (NCT06855277)
- Testing
- AAA817, ARPI, Standard of Care
- Where
- 106 sites in United States, Australia and 10 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Depression
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
The purpose of this trial is to conduct an assessment of brain nociceptin/orphanin FQ peptide (NOP) receptor occupancy (RO) in healthy subjects.
- Trial name
- NCT01404091
- Testing
- LY2940094
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BlackThorn Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS
The goal of this study is to evaluate the safety of using the [5-cyano-N-(4-(4-[11C]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide] ([11C]CPPC) radiotracer in positron emission tomography (PET) imaging of…
- Trial name
- NCT04749433
- Testing
- [11C]CPPC Injection
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Renal Cell Carcinoma
Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Considering its origination from kidney, an organ with intense physiological uptake and excretion of 68Ga-PSMA, this study aims to evaluate the uptake of…
- Trial name
- NCT05170555
- Testing
- 68Ga-PSMA, 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided…
- Trial name
- NCT06105918
- Testing
- Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Prostate Cancer Metastatic
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and…
- Trial name
- LUTRAC (NCT06260410)
- Testing
- Blood draw for ctDNA and circulating tumor cell collection.
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer, Prostatic Neoplasms
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastases
- Trial name
- NCT07863986
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry
- Where
- Lithuania
- Volunteers
- 70 people
- Sponsor
- Lithuanian University of Health Sciences
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Prostate Cancer
Radioligand fOr locAl raDiorecurrent proStaTe cancER
Approximately 50-60% of men undergoing salvage brachytherapy post cancer recurrence to the prostate have the disease controlled at 5 years.
- Trial name
- ROADSTER (NCT05230251)
- Testing
- 177Lu-PNT2002, High Dose Radiation
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Glenn Bauman
Amyotrophic Lateral Sclerosis
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
- Trial name
- NCT04066244
- Testing
- BLZ945
- Where
- 4 sites in United States, Finland and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate…
- Trial name
- PSMAddition (NCT04720157)
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Where
- 167 sites in United States, Austria and 17 more
- Volunteers
- 1,140 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, mCRPC
Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer
Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC).
- Trial name
- NCT06377683
- Testing
- 177Lu-Dansyl-PSMA radioligand therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Acute Leukemia
Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.
CXCR4 inhibition may represent a new therapeutic strategy in acute leukemia (AL) patients, not only by increasing chemosensitivity but also by preventing relapse of the disease by disruption of the interaction of residual…
- Trial name
- PENTILULA (NCT06356922)
- Testing
- Experimental drug [177Lu]Lu-PentixaTher
- Where
- 4 sites in France
- Volunteers
- 21 people
- Sponsor
- Nantes University Hospital
Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
- Trial name
- NCT06879041
- Testing
- AZD2287, AZD2275, AZD2284
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 136 people
- Sponsor
- AstraZeneca